Wells Fargo
BIOC

Wells Fargo’s Biocept, Inc. BIOC Stock Holding History

Wells Fargo’s Portfolio BIOC Stock Details BIOC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-11
Closed -$14 – 7848
2023
Q3 		$14 Buy
11
+7
+175% +$8 ﹤0.01% 7320
2023
Q2 		$5 Hold
4
– – ﹤0.01% 7521
2023
Q1 		$40 Hold
4
– – ﹤0.01% 7175
2022
Q4 		$61 Hold
4
– – ﹤0.01% 6947
2022
Q3 		$0 Hold
4
– – ﹤0.01% 7758
2022
Q2 		$0 Buy
4
+1
+33% +$46 ﹤0.01% 7855
2022
Q1 		$0 Hold
3
– – ﹤0.01% 8173
2021
Q4 		$0 Hold
3
– – ﹤0.01% 8100
2021
Q3 		$0 Hold
3
– – ﹤0.01% 7776
2021
Q2 		$0 Hold
3
– – ﹤0.01% 7707
2021
Q1 		$0 Hold
3
– – ﹤0.01% 7613
2020
Q4 		$0 Hold
3
– – ﹤0.01% 7255
2020
Q3 		$0 Buy
3
+2
+200% +$404 ﹤0.01% 7140
2020
Q2 		$0 Hold
1
– – ﹤0.01% 7035
2020
Q1 		$0 Buy
+1
New +$102 ﹤0.01% 7038
2014
Q2 		– Hold
0
– -$1K – 6341
2014
Q1 		– Hold
0
– – – 5798

Wells Fargo's BIOC Position: Q4 2023 in Review

Wells Fargo sold out of Biocept, Inc. (BIOC) in Q4 2023, closing a stake of 11 shares — an estimated $14 sold.

Wells Fargo first reported a position in BIOC in Q1 2020 and held it in 15 quarters. The position peaked at $61 in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOC as of Q4 2023.

  • Wells Fargo reported no remaining Biocept, Inc. position as of Q4 2023 after selling out during the quarter.
  • Wells Fargo sold 11 Biocept, Inc. shares in Q4 2023, an estimated $14.
  • Wells Fargo first reported a position in Biocept, Inc. in Q1 2020 and held it in 15 quarters.
  • Wells Fargo's Biocept, Inc. position peaked at $61 in Q4 2022.
  • 0 funds tracked by Wall St. Rank held Biocept, Inc. as of Q4 2023.

Based on Wells Fargo's 13F filing for Q4 2023, filed 9 Feb 2024.